“Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s421, https://doi.org/10.25251/skin.8.supp.421.